MX2022000429A - Telmisartan para el tratamiento de la enfermedad renal cronica en perros. - Google Patents
Telmisartan para el tratamiento de la enfermedad renal cronica en perros.Info
- Publication number
- MX2022000429A MX2022000429A MX2022000429A MX2022000429A MX2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A MX 2022000429 A MX2022000429 A MX 2022000429A
- Authority
- MX
- Mexico
- Prior art keywords
- telmisartan
- treatment
- dogs
- kidney disease
- chronic kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871752P | 2019-07-09 | 2019-07-09 | |
| PCT/US2020/030579 WO2021006941A1 (en) | 2019-07-09 | 2020-04-30 | Telmisartan for the treatment of chronic kidney disease in dogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000429A true MX2022000429A (es) | 2022-04-25 |
Family
ID=70775531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000429A MX2022000429A (es) | 2019-07-09 | 2020-04-30 | Telmisartan para el tratamiento de la enfermedad renal cronica en perros. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220218671A1 (https=) |
| EP (1) | EP3996705A1 (https=) |
| JP (2) | JP2022540074A (https=) |
| KR (1) | KR20220054291A (https=) |
| CN (1) | CN114450004A (https=) |
| BR (1) | BR112022000315A2 (https=) |
| CA (1) | CA3142876A1 (https=) |
| MX (1) | MX2022000429A (https=) |
| TW (1) | TW202116305A (https=) |
| WO (1) | WO2021006941A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220054292A (ko) | 2019-07-09 | 2022-05-02 | 베링거잉겔하임베트메디카게엠베하 | 개의 고혈압 치료를 위한 텔미사르탄 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3648761T (pt) | 2017-07-07 | 2024-06-05 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartan para a profilaxia ou tratamento de hipertensão em gatos |
-
2020
- 2020-04-30 MX MX2022000429A patent/MX2022000429A/es unknown
- 2020-04-30 WO PCT/US2020/030579 patent/WO2021006941A1/en not_active Ceased
- 2020-04-30 CN CN202080049786.XA patent/CN114450004A/zh active Pending
- 2020-04-30 BR BR112022000315A patent/BR112022000315A2/pt unknown
- 2020-04-30 US US17/596,351 patent/US20220218671A1/en active Pending
- 2020-04-30 EP EP20727049.7A patent/EP3996705A1/en active Pending
- 2020-04-30 KR KR1020227004466A patent/KR20220054291A/ko active Pending
- 2020-04-30 CA CA3142876A patent/CA3142876A1/en active Pending
- 2020-04-30 JP JP2021578227A patent/JP2022540074A/ja active Pending
- 2020-04-30 TW TW109114512A patent/TW202116305A/zh unknown
-
2025
- 2025-04-17 JP JP2025068236A patent/JP2025120167A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220218671A1 (en) | 2022-07-14 |
| EP3996705A1 (en) | 2022-05-18 |
| KR20220054291A (ko) | 2022-05-02 |
| JP2022540074A (ja) | 2022-09-14 |
| CA3142876A1 (en) | 2021-01-14 |
| BR112022000315A2 (pt) | 2022-02-22 |
| CN114450004A (zh) | 2022-05-06 |
| AU2020311280A1 (en) | 2022-02-24 |
| TW202116305A (zh) | 2021-05-01 |
| JP2025120167A (ja) | 2025-08-15 |
| WO2021006941A1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| BR112016029067A2 (pt) | ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios? | |
| NZ602029A (en) | Use of meloxicam for the long-term treatment of kidney disorders in cats | |
| MX381440B (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| NO20082536L (no) | Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser | |
| EA201390618A1 (ru) | Режимы дозирования при лечении офтальмологического сосудистого заболевания | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| EA202190398A1 (ru) | Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4 | |
| MX2022000429A (es) | Telmisartan para el tratamiento de la enfermedad renal cronica en perros. | |
| MX381526B (es) | Agente para suprimir el progreso de o para mejorar la enfermedad renal crónica. | |
| AR122933A1 (es) | Métodos para tratar la enfermedad cardiovascular | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| MX378409B (es) | Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa. |